AMBRX BIOPHARMA INC
COM · CUSIP 641871108
0
institutional holders
-68 vs Q4 2023
—reported value*
0 new
0 added
0 reduced
68 sold out
net sold ≈ $912.6m (-64.1m shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.
Trends to Q1 2024
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2023 | 68 |
| Q1 2024 | 0 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
CallsPuts
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q2 2023 | $0 | $0 | — |
| Q3 2023 | $0 | $0 | — |
| Q4 2023 | $4.7m | $3.7m | 0.79 |
| Q1 2024 | $0 | $0 | — |
Biggest buyers
| None |
Biggest sellers
| Darwin Global Management, Ltd. | Sold out | -16.7m |
| Cormorant Asset Management, LP | Sold out | -11.2m |
| Paradigm Biocapital Advisors LP | Sold out | -4.4m |
| D. E. Shaw & Co., Inc. | Sold out | -4.2m |
| Deep Track Capital, LP | Sold out | -3.7m |
| Nextech Invest Ltd. | Sold out | -3.1m |
| Balyasny Asset Management L.P. | Sold out | -2.2m |
| Logos Global Management LP | Sold out | -2.1m |
| Venrock Adviser, LLC | Sold out | -2.1m |
| CITADEL ADVISORS LLC | Sold out | -2.0m |
Holders, Q1 2024
| Manager | Shares | Change |
|---|